17 results about "Bone Marrow Stromal Cell" patented technology

The invention discloses application of a Chibby1 (CBY1) inhibitor in preparation of an anti-osteoporosis medicine for promoting bone formation, and belongs to the technical field of biological medicines. It is found for the first time that CBY1 can inhibit bone marrow stromal cells from differentiating into osteoblasts, and bone marrow stromal cells with CBY1 gene silencing are increased in osteoblast differentiation. According to the invention, it is proposed for the first time that osteoblast differentiation can be promoted by reducing CBY1 expression or inhibiting the CBY1 function, and the CBY1 inhibitor has the potential of increasing osteogenic activity and preventing and treating osteoporosis by inhibiting CBY1 expression or inhibiting the CBY1 function.

The invention discloses an operation method for splitting an oral implant bone, which comprises the following steps of: preparing an ultrathin bone sheet of which the buccal side is less than 1mm, reserving physiological connection between periosteum and the bone sheet, and constructing a periosteum bone flap. The periosteum flap is of a natural barrier membrane structure, and integrates the function of a bone sheet rigid support and the semi-permeable membrane characteristic of the periosteum. The buccal ultrathin bone sheet is connected with the basal bone, is a rigid support structure, supports an osteogenesis space, and can provide bone marrow stroma cells to participate in bone defect repair. Physiological attachment of periosteum is not only a blood supply source of an inner side bone sheet, but also exerts the characteristics of a semi-permeable membrane, replaces an artificial barrier membrane to stop fiber tissue from growing in, and follows the PASS principle of the GBR technology, so that the operation risk is reduced, the use of the artificial barrier membrane is reduced, the adaptation disease of bone splitting is widened, the absorption of buccal side bones is reduced, and the bone splitting effect is improved. And the clinical effect of bone defect repair is improved.

An antibacterial artificial nano-cell and a preparation method therefor. The antibacterial artificial nano-cell is prepared by the following steps: mixing polyvinylpyrrolidone or an aqueous solution thereof, CuCl2·2H2O or an aqueous solution thereof, FeCl2·4H2O or an aqueous solution thereof, Elesclomol or a DMSO solution thereof, NaOH or an aqueous solution thereof, and H2O2 or an aqueous solution thereof, uniformly stirring the mixture, followed by washing, ultrafiltration and centrifugation to obtain nanoparticles, uniformly mixing the nanoparticles with cell membranes prepared from bone marrow stromal cells, and carrying out ultrasonic incubation and extrusion to obtain the antibacterial artificial nano-cells.

This invention discloses an antibody-engineered bone marrow stromal cell and its applications, belonging to the field of biomedical technology. Using bone marrow stromal cells as a biological carrier, this invention externally modifies them with immune checkpoint antibodies to form an antibody-coated engineered cell preparation, thereby achieving targeted and precise mitochondrial delivery of exhausted T cells. This cell preparation can be used in combination with other immunotherapies that can induce T cell exhaustion, such as tumor immunotherapies and CAR-T therapy, to help enhance their anti-tumor efficacy and duration of effect.

The application discloses a piezoelectric porous scaffold with high efficient osteogenesis and a preparation method thereof. The piezoelectric porous scaffold is obtained by mixing a biological component and a piezoelectric component through an adhesive, sintering and then performing polarization treatment. The piezoelectric porous scaffold can efficiently load and adsorb bioactive protein factors, realizes effective release of the protein, and has piezoelectric performance and osteogenesis activity. Under the multiple effects of the piezoelectric effect, the porous structure and the bioactivity of the protein of the scaffold, the piezoelectric porous scaffold can quickly start early response of bone marrow stromal cells in a synergistic manner, and then promote cell adhesion, proliferation and osteogenic differentiation. The piezoelectric porous scaffold has important significance for efficient and rapid repair of large bone defects, bone nonunion and other bone defects.

The invention provides a human bone marrow stroma cell line and application thereof. The invention successfully establishes the human bone marrow stromal cell line hFSC022 capable of efficiently promoting in-vitro hematopoietic generation and induced differentiation of hematopoietic cells for the first time. The human bone marrow stromal cell line established by the invention is derived from waste human bone marrow tissues, and compared with mouse trophoblast cells, the human bone marrow stromal cell line has no species crossing risk, has higher safety and is more suitable for clinical research and use; compared with mouse trophoblast cells or stromal cells derived from other bone marrow tissues, the stromal cells have higher hematopoietic generation promoting capacity; in-vitro culture is free of animal-derived components, cell therapy level requirements of clinical application are met, and the method is more suitable for clinical research and application. Meanwhile, the cell line established by the invention can be used as a trophoblast or a combined medicine, is used for supporting in-vitro maintenance or proliferation of human hematopoietic stem / progenitor cells and inducing differentiation of human pluripotent stem cells to hematopoietic cells, and has a wide application prospect in the fields of in-vitro hematopoietic generation and cell therapy.

Clonal hematopoiesis is an age-related condition caused by somatic mutations conferring a clone-selective advantage to hematopoietic stem cells. Although clonal hematopoiesis is a benign disorder, the risk of developing leukemia, such as acute myeloid leukemia (AML), in an individual affected by clonal hematopoiesis is increased. In some aspects, the disclosure provides methods for inhibiting clonal hematopoiesis using senescent cell scavengers to target senescence of bone marrow stromal cells.

The invention discloses application of an RUFY4 gene in promoting osteogenic differentiation of osteoblasts, and relates to the field of osteoporosis treatment. The method comprises the following steps: constructing an overexpression lentiviral vector containing RUFY4; mouse bone marrow stromal stem cells are transfected by using the RUFY4 gene, so that RUFY4 overexpressed KUSA-O cells are obtained; the osteogenic differentiation capacity of KUSA-O cells is detected through ALP dyeing and alizarin red S dyeing, and the osteogenic differentiation promoting effect of the RUFY4 is verified. Furthermore, ossification-related gene and protein expression are detected through Western blot, qRT-PCR (quantitative reverse transcription-polymerase chain reaction) and immunofluorescence, and it is clear that RUFY4 promotes osteogenic differentiation through PI3K / AKT and / Wnt / beta-catenin signal channels. Transcriptomics analysis proves that the RUFY4 has a positive regulation effect on osteoblast differentiation, bone formation and bone density recovery of osteoporosis patients are facilitated, and a new strategy is provided for osteoporosis targeted therapeutic drugs.

The application belongs to the field of virus culture, and provides a CHO cell, an application, and a virus culture method. In the CHO cell, a gene of bone marrow stromal cell antigen 2 is inactivated. The virus culture method comprises the following steps: (1) constructing the CHO cell in which the gene of bone marrow stromal cell antigen 2 is inactivated, and performing sequencing identification; (2) detecting the proliferation activity of the CHO cell in which the gene of bone marrow stromal cell antigen 2 is inactivated; (3) culturing the CHO cell in which the gene of bone marrow stromal cell antigen 2 is inactivated, and then infecting the virus; and (4) detecting the proliferation of virus nucleic acid and the virus titer. The CHO cell in which the gene of bone marrow stromal cell antigen 2 is knocked out is used to culture and expand the virus, the restriction of the CHO cell on virus budding is released, and the isolation efficiency of the influenza virus and the virus infection titer are improved.

The invention discloses a bispecific bionic nanomaterial and a preparation method and application thereof, and belongs to the field of biological medicine.The bispecific bionic nanomaterial is composed of a marrow stromal cell membrane modified enzyme-loaded porphyrin covalent organic framework, an anti-CD3 antibody and an anti-PD-L1 antibody, the enzyme-loaded porphyrinyl covalent organic framework is loaded with glucose oxidase, and the antibody is anchored on a phospholipid bilayer of the enzyme-loaded porphyrinyl covalent organic framework modified by a cell membrane through a physical effect; the bispecific bionic nano material prepared by the invention can block a CXCR4 / CXCL12 axis and inhibit migration and adhesion of leukemia cells; according to the bispecific bionic nanomaterial, hydrogen peroxide generated by decomposition of glucose is converted into hydroxyl radicals for chemical kinetic treatment by utilizing peroxidase-like activity of a porphyrin-based covalent organic framework, and T cells are redirected to leukemia cells to play a killing role.

The invention discloses application of a bone cell specific Wnt signal in critical bone defect repair, and relates to the field of medicine. A 3D printed composite scaffold for use in the treatment of critical bone defects, bone nonunion or osteoporosis, which is applied in the form of a 3D printed composite scaffold comprising bio-ink and polycaprolactone PCL, the bio-ink comprising a bone-derived acellular extracellular matrix (dECM) in a drug-activated bone cell Wnt signal. The dECM bio-ink based on drug activated bone cell Wnt signals and the PCL are used for constructing the composite scaffold through 3D printing, the composite scaffold is used for repairing critical bone defects and retaining a microstructure and bioactive components of a natural bone matrix, and osteogenic differentiation, osteoclast generation, angiogenesis and neurogenesis of bone marrow stromal cells BMSCs can be remarkably promoted.

Clonal hematopoiesis is an age-related condition caused by somatic mutations that give a hematopoietic stem cell a clonal selective advantage. While clonal hematopoiesis is a benign condition, individuals affected by it have an increased risk of developing blood cancers, such as acute myeloid leukemia (AML). The present disclosure provides, in some aspects, methods for inhibiting clonal hematopoiesis using a senolytic agent to target senescence of bone marrow stromal cells.

This invention discloses a method and application for inducing human pluripotent stem cells to differentiate into bone marrow stromal cells, relating to the field of biomedical technology. The induction method of this invention includes: firstly, obtaining human pluripotent stem cells, and then inducing their differentiation into endothelial cells; then, using TGF-β to induce the endothelial cells to differentiate into bone marrow stromal cells, thus obtaining the cells. Bone marrow stromal cells obtained based on the induction method of this invention can not only effectively promote the expansion and multi-lineage differentiation of hematopoietic stem cells and reverse the aging phenotype of senescent hematopoietic stem cells, but also promote the proliferation of immune cells such as T cells and NK cells, showing great application potential in hematopoietic reconstitution, immune regulation, and anti-aging intervention.

To provide a pharmaceutical composition for use in a method for modulating an inflammatory stress response within a hematopoietic bone marrow microenvironment comprising bone marrow endothelial cells (BMECs), hematopoietic stem cells (HSCs), and bone marrow stromal cells following a myelosuppressive insult.SOLUTION: Wherein the pharmaceutical composition comprises pharmacological means for modulating the inflammatory stress response comprising administration of recombinant or synthetic Clec11 alpha stem cell factor (SCGF) and / or genetic means comprising suppression of endothelial NF - κ B signaling; The pharmaceutical composition protects the bone marrow (BM) hematopoietic compartment by inhibiting NF - κ B in endothelial cells, suppressing downstream NF - κ B signaling in the BM, down-regulating target NF - κ B genes in the BM, or both, and promotes recovery after myelosuppressive injury and resolves inflammation.SELECTED DRAWING: None

The invention discloses a bone marrow stromal cell membrane bionic drug-loading CX4945 nano delivery system as well as a preparation method and application thereof. The bone marrow stromal cell membrane bionic drug-loading CX4945 nano delivery system takes a CX4945 drug coated by a high-molecular polymer as a core and a stromal cell membrane as a shell layer, so that the CX4945 can be slowly released, the half-life period of the drug is prolonged, and the medication frequency of the CX4945 is reduced; through specific binding of CXCL12 on a matrix cell membrane and CXCR4 over-expressed on the surface of a B-ALL cell, the uptake of the B-ALL cell to a CX4945 drug is improved, the killing of the drug to tumor cells is enhanced, and accurate delivery of the CX4945 drug is realized; the homing of B-ALL cells can be prevented by blocking a CXCR4 / CXCL12 biological axis, and the problems of transfer, relapse, drug resistance and the like of the B-ALL cells are solved.

The application discloses application of a Chibby1 (CBY1) inhibitor in preparation of an anti-osteoporosis drug for promoting bone formation, and belongs to the technical field of biological medicines. It is found for the first time that CBY1 can inhibit differentiation of bone marrow stromal cells into osteoblasts, and that bone marrow stromal cells with CBY1 gene silencing have increased osteogenic differentiation. It is proposed for the first time that reducing CBY1 expression or inhibiting the function of CBY1 can promote differentiation of osteoblasts, and that a CBY1 inhibitor has the potential of increasing osteogenic activity and preventing and treating osteoporosis by inhibiting CBY1 expression or inhibiting the function of CBY1.

The invention discloses a nutritional therapy-based functional potion for benefiting qi and nourishing blood and a preparation process thereof, and belongs to the technical field of functional foods.The preparation process comprises the following steps: preparing beta-cyclodextrin, ergothioneine and an iron source into an inclusion compound; the inclusion compound, the colloid, the red ginseng, the red date concentrated juice, the lemon concentrated juice and the like are added into a reaction container to form a synergistic effect mechanism of tonifying qi, generating blood and promoting absorption, and the traditional Chinese medicine composition has a more remarkable hematopoietic function improvement effect compared with a single iron agent or a traditional blood replenishing traditional Chinese medicine; the ergothioneine can remarkably promote absorption of iron, and the iron source and the ergothioneine are prepared into the inclusion compound, so that the stability of the ergothioneine and the iron is improved, the damage of gastric acid is avoided, and the bioavailability of the potion is improved; through synergistic compatibility of the active component of red ginseng and iron, the multiplication capacity of bone marrow stroma cells can be remarkably enhanced, and the qi and blood biochemical function of the body is improved; ginsenoside contained in the red ginseng has the effect of promoting hematopoiesis and can activate proliferation and differentiation of hematopoietic stem cells.